TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,736

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions
Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions
DRUG

Docetaxel

Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer

DRUG

Carboplatin

Carboplatin is a deoxyribonucleic acid (DNA) synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.

DRUG

Epirubicin

Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.

DRUG

Cyclophosphamide

Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.

Trial Locations (1)

200032

RECRUITING

Breast cancer institute of Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER